Mostrar el registro sencillo del ítem

Artículo

dc.creatorFernández-Cuenca, Felipees
dc.creatorLópez Hernández, Inmaculadaes
dc.creatorCercenado, Emiliaes
dc.creatorConejo Gonzalo, Mª Carmenes
dc.creatorTormo, Nuriaes
dc.creatorGimeno, Conchaes
dc.creatorPascual Hernández, Álvaroes
dc.date.accessioned2023-01-10T15:18:33Z
dc.date.available2023-01-10T15:18:33Z
dc.date.issued2021-02-08
dc.identifier.citationFernández-Cuenca, F., López Hernández, I., Cercenado, E., Conejo Gonzalo, M.C., Tormo, N., Gimeno, C. y Pascual Hernández, Á. (2021). Reporting antimicrobial susceptibilities and resistance phenotypes in Staphylococcus spp.: a nationwide proficiency study. Journal of Antimicrobial Chemotherapy, 76 (5), 1187-1196. https://doi.org/10.1093/jac/dkab017.
dc.identifier.issn0305-7453;1460-2091es
dc.identifier.urihttps://hdl.handle.net/11441/141095
dc.description.abstractObjectives To evaluate the proficiency of microbiology laboratories in Spain in antimicrobial susceptibility testing (AST) of Staphylococcus spp. Materials and methods Eight Staphylococcus spp. with different resistance mechanisms were selected: six Staphylococcus aureus (CC-01/mecA, CC-02/mecC, CC-03/BORSA, CC-04/MLSBi, CC-06/blaZ and CC-07/linezolid resistant, cfr); one Staphylococcus epidermidis (CC-05/linezolid resistant, 23S rRNA mutation); and one Staphylococcus capitis (CC-08/daptomycin non-susceptible). Fifty-one laboratories were asked to report: (i) AST system used; (ii) antimicrobial MICs; (iii) breakpoints used (CLSI or EUCAST); and (iv) clinical category. Minor, major and very major errors (mEs, MEs and VMEs, respectively) were determined. Results The greatest MIC discrepancies found were: (i) by AST method: 19.4% (gradient diffusion); (ii) by antimicrobial agent: daptomycin (21.3%) and oxacillin (20.6%); and (iii) by isolate: CC-07/cfr (48.0%). The greatest error rates were: (i) by AST method: gradient diffusion (4.3% and 5.1% VMEs, using EUCAST and CLSI, respectively); (ii) by breakpoint: 3.8% EUCAST and 2.3% CLSI; (iii) by error type: mEs (0.8% EUCAST and 1.0% CLSI), MEs (1.8% EUCAST and 0.7% CLSI) and VMEs (1.2% EUCAST and 0.6% CLSI); (iii) by antimicrobial agent: VMEs (4.7% linezolid and 4.3% oxacillin using EUCAST); MEs (14.3% fosfomycin, 9.1% tobramycin and 5.7% gentamicin using EUCAST); and mEs (22.6% amikacin using EUCAST). Conclusions Clinical microbiology laboratories should improve their ability to determine the susceptibility of Staphylococcus spp. to some antimicrobial agents to avoid reporting false-susceptible or false-resistant results. The greatest discrepancies and errors were associated with gradient diffusion, EUCAST breakpoints and some antimicrobials (mEs for aminoglycosides; MEs for fosfomycin, aminoglycosides and oxacillin; and VMEs for linezolid and oxacillin).es
dc.formatapplication/pdfes
dc.format.extent10 p.es
dc.language.isoenges
dc.publisherOxford University Presses
dc.relation.ispartofJournal of Antimicrobial Chemotherapy, 76 (5), 1187-1196.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectphenotypees
dc.subjectgentamicin sulfate (usp)es
dc.subjectamikacines
dc.subjectdiffusiones
dc.subjectchromatographyes
dc.subjectmicellar electrokinetic capillaryes
dc.subjectdaptomycines
dc.subjectfosfomycines
dc.subjectgentamicinses
dc.subjectlaboratoryes
dc.subjectoxacillines
dc.subjectstaphylococcuses
dc.subjectmicrobiologyes
dc.subjecttobramycines
dc.subjectlinezolides
dc.subjectantimicrobialses
dc.subjectchief complaintes
dc.subjectmalnutrition-inflammation-cachexia syndromees
dc.titleReporting antimicrobial susceptibilities and resistance phenotypes in Staphylococcus spp.: a nationwide proficiency studyes
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Microbiologíaes
dc.relation.projectIDRD 16/0016es
dc.relation.publisherversionhttps://academic.oup.com/jac/article/76/5/1187/6130710es
dc.identifier.doi10.1093/jac/dkab017es
dc.journaltitleJournal of Antimicrobial Chemotherapyes
dc.publication.volumen76es
dc.publication.issue5es
dc.publication.initialPage1187es
dc.publication.endPage1196es
dc.contributor.funderInstituto de Salud Carlos IIIes

FicherosTamañoFormatoVerDescripción
Reporting antimicrobial suscep ...336.7KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional